Yuen B H
Department of Obstetrics and Gynaecology, Faculty of Medicine, University of British Columbia, Vancouver, Canada.
Int J Fertil. 1986 Mar-Apr;31(1):67-70.
Prolactin levels were measured by radioimmunoassay in paired breast milk and plasma samples of 11 hyperprolactinemic women with galactorrhea and various menstrual disorders (amenorrhea, n = 8; oligomenorrhea, n = 2; luteal phase defect, n = 1) before and during treatment with bromocriptine (Parlodel, Sandoz). Pretreatment levels of prolactin in the milk and plasma were 80 +/- 13 ng/mL (mean +/- SEM) and 47 +/- 7 ng/mL (P less than 0.05), respectively. While on treatment, the concentration gradient for prolactin remained in favour of the milk, with values for milk and plasma 59 +/- 11 and 29 +/- 3 ng/mL (P less than 0.01), respectively. Thus, bromocriptine lowered the prolactin concentrations in both breast milk and plasma. Since prolactin in milk is biologically active, these findings may be relevant to the initiation and maintenance of lactation in women with abnormal lactogenesis.
采用放射免疫分析法对11名患有高催乳素血症且伴有溢乳及各种月经紊乱（闭经8例；月经过少2例；黄体期缺陷1例）的女性，在服用溴隐亭（帕罗西汀，山德士公司）治疗前及治疗期间的配对母乳和血浆样本中的催乳素水平进行了测量。治疗前母乳和血浆中的催乳素水平分别为80±13 ng/mL（均值±标准误）和47±7 ng/mL（P<0.05）。在治疗期间，催乳素的浓度梯度仍有利于母乳，母乳和血浆中的值分别为59±11和29±3 ng/mL（P<0.01）。因此，溴隐亭降低了母乳和血浆中的催乳素浓度。由于母乳中的催乳素具有生物活性，这些发现可能与泌乳发生异常的女性泌乳的启动和维持有关。
